Debra T. Chao

5.2k total citations · 3 hit papers
28 papers, 4.3k citations indexed

About

Debra T. Chao is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Immunology. According to data from OpenAlex, Debra T. Chao has authored 28 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 11 papers in Radiology, Nuclear Medicine and Imaging and 11 papers in Immunology. Recurrent topics in Debra T. Chao's work include Monoclonal and Polyclonal Antibodies Research (11 papers), Immune Cell Function and Interaction (6 papers) and Immunotherapy and Immune Responses (6 papers). Debra T. Chao is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (11 papers), Immune Cell Function and Interaction (6 papers) and Immunotherapy and Immune Responses (6 papers). Debra T. Chao collaborates with scholars based in United States, France and Netherlands. Debra T. Chao's co-authors include Stanley J. Korsmeyer, Jialing Xiang, Curt Milliman, S J Korsmeyer, Xiaoming Yin, Kai Wang, Lawrence Boise, Craig B. Thompson, Gerald P. Linette and S J Korsmeyer and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

Debra T. Chao

28 papers receiving 4.2k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

BCL-2 FAMILY: Regulators of Cell Death

1998 1.5k citations Debra T. Chao, Stanley J. Korsmeyer Annual Review of Immunology profile →
BAX-induced cell death may not require interleukin 1β-converting enzyme-like proteases

1996 805 citations Debra T. Chao, Stanley J. Korsmeyer et al. profile →
BID: a novel BH3 domain-only death agonist.

1996 779 citations Kai Wang, Xiaoming Yin et al. Genes & Development profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Debra T. Chao United States	18	2.9k	1.2k	1.1k	505	352	28	4.3k
Irmela Jeremias Germany	34	2.6k 0.9×	1.1k 0.9×	1.0k 0.9×	724 1.4×	456 1.3×	103	4.0k
Angela Coxon United States	34	1.9k 0.6×	1.3k 1.0×	1.2k 1.1×	449 0.9×	307 0.9×	92	4.3k
Heidi Kiil Blomhoff Norway	37	2.6k 0.9×	1.2k 1.0×	720 0.7×	375 0.7×	286 0.8×	106	4.2k
Xiaoling Song China	32	3.0k 1.0×	1.3k 1.0×	1.5k 1.4×	777 1.5×	222 0.6×	79	4.6k
Véronique Baron France	33	2.0k 0.7×	1.1k 0.9×	772 0.7×	463 0.9×	226 0.6×	57	3.7k
Tomohiro Takahashi Japan	7	2.4k 0.8×	2.0k 1.7×	626 0.6×	505 1.0×	415 1.2×	13	4.1k
David S. Ucker United States	29	2.3k 0.8×	1.5k 1.2×	649 0.6×	385 0.8×	281 0.8×	61	5.1k
Erhard Hofer Austria	33	2.8k 1.0×	1.7k 1.4×	928 0.9×	770 1.5×	239 0.7×	72	5.3k
Ann Zeuner Italy	35	2.4k 0.8×	879 0.7×	1.4k 1.3×	867 1.7×	193 0.5×	72	4.3k
Eric C. LaCasse Canada	34	4.0k 1.4×	1.2k 1.0×	1.3k 1.2×	994 2.0×	500 1.4×	65	5.2k

Countries citing papers authored by Debra T. Chao

Since Specialization

Citations

This map shows the geographic impact of Debra T. Chao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Debra T. Chao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Debra T. Chao more than expected).

Fields of papers citing papers by Debra T. Chao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Debra T. Chao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Debra T. Chao. The network helps show where Debra T. Chao may publish in the future.

Co-authorship network of co-authors of Debra T. Chao

This figure shows the co-authorship network connecting the top 25 collaborators of Debra T. Chao. A scholar is included among the top collaborators of Debra T. Chao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Debra T. Chao. Debra T. Chao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Smith, Laura E., Zoltán Dezső, Xu Shi, et al.. (2021). VISTA is an activating receptor in human monocytes. The Journal of Experimental Medicine. 218(8). 25 indexed citations

Thakur, Archana, Melvin Fox, Enrico L. DiGiammarino, et al.. (2020). Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity. Molecular Cancer Therapeutics. 19(4). 1040–1051. 30 indexed citations

Ye, Shiming, Nicole A. Belmar, Mien Sho, et al.. (2019). A Bispecific Molecule Targeting CD40 and Tumor Antigen Mesothelin Enhances Tumor-Specific Immunity. Cancer Immunology Research. 7(11). 1864–1875. 40 indexed citations

Purcell, James W., Jonathan A. Hickson, Melvin Fox, et al.. (2018). LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody–Drug Conjugates. Cancer Research. 78(14). 4059–4072. 136 indexed citations

Ye, Shiming, Melvin Fox, Nicole A. Belmar, et al.. (2017). Enavatuzumab, a Humanized Anti-TWEAK Receptor Monoclonal Antibody, Exerts Antitumor Activity through Attracting and Activating Innate Immune Effector Cells. Journal of Immunology Research. 2017. 1–14. 12 indexed citations

Purcell, James W., Melvin Fox, Peter Lambert, et al.. (2014). Nuclear Factor κB is Required for Tumor Growth Inhibition Mediated by Enavatuzumab (PDL192), a Humanized Monoclonal Antibody to TweakR. Frontiers in Immunology. 4. 505–505. 12 indexed citations

Balasa, Balaji, Nicole A. Belmar, Melvin Fox, et al.. (2014). Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways. Cancer Immunology Immunotherapy. 64(1). 61–73. 123 indexed citations

Woo, Jacky, Michel Vierboom, Hakju Kwon, et al.. (2013). PDL241, a novel humanized monoclonal antibody, reveals CD319 as a therapeutic target for rheumatoid arthritis. Arthritis Research & Therapy. 15(6). R207–R207. 15 indexed citations

Chao, Debra T., Mien Sho, Donghee Choi, et al.. (2012). Expression of TweakR in breast cancer and preclinical activity of enavatuzumab, a humanized anti-TweakR mAb. Journal of Cancer Research and Clinical Oncology. 139(2). 315–325. 28 indexed citations

10.

Besse, Benjamin, L. Claire Tsao, Debra T. Chao, et al.. (2012). Phase Ib safety and pharmacokinetic study of volociximab, an anti-α5β1 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer. Annals of Oncology. 24(1). 90–96. 68 indexed citations

11.

Culp, Patricia, Donghee Choi, Yongke Zhang, et al.. (2010). Antibodies to TWEAK Receptor Inhibit Human Tumor Growth through Dual Mechanisms. Clinical Cancer Research. 16(2). 497–508. 62 indexed citations

12.

Rhee, Frits van, Susann Szmania, Myles Dillon, et al.. (2009). Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Molecular Cancer Therapeutics. 8(9). 2616–2624. 142 indexed citations

13.

Chao, Debra T., Xiaohong Ma, Olga Li, Hyunjoo Park, & Debbie A. Law. (2009). Functional Characterization of N297A, A Murine Surrogate for low-Fc Binding Anti-Human CD3 Antibodies. Immunological Investigations. 38(1). 76–92. 25 indexed citations

14.

Belmar, Nicole A., Debra T. Chao, Olga Li, et al.. (2009). Dissociation of efficacy and cytokine release mediated by an Fc-modified anti-CD3 mAb in a chronic experimental autoimmune encephalomyelitis model. Journal of Neuroimmunology. 212(1-2). 65–73. 6 indexed citations

15.

Bhaskar, Vinay, Dong Zhang, Melvin Fox, et al.. (2007). A function blocking anti-mouse integrin α5β1 antibody inhibits angiogenesis and impedes tumor growth in vivo. Journal of Translational Medicine. 5(1). 61–61. 66 indexed citations

16.

McCabe, Dominick J. H., Nicholas C. Turner, Debra T. Chao, et al.. (2004). Paraneoplastic “stiff person syndrome” with metastatic adenocarcinoma and anti-Ri antibodies. Neurology. 62(8). 1402–1404. 32 indexed citations

17.

Chao, Debra T. & Stanley J. Korsmeyer. (1998). BCL-2 FAMILY: Regulators of Cell Death. Annual Review of Immunology. 16(1). 395–419. 1452 indexed citations breakdown →

18.

Chao, Debra T.. (1997). BCL-XL-regulated apoptosis in T cell development. International Immunology. 9(9). 1375–1384. 53 indexed citations

19.

Wang, Kai, Xiaoming Yin, Debra T. Chao, Curt Milliman, & S J Korsmeyer. (1996). BID: a novel BH3 domain-only death agonist.. Genes & Development. 10(22). 2859–2869. 779 indexed citations breakdown →

20.

Chao, Debra T., Gerald P. Linette, Lawrence Boise, et al.. (1995). Bcl-XL and Bcl-2 repress a common pathway of cell death.. The Journal of Experimental Medicine. 182(3). 821–828. 355 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact